Consensus or Controversy, Issue 2: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Management of Transplant-Ineligible Patients with Multiple Myeloma and Waldenström Macroglobulinemia

To see the complete question and investigator responses, move your mouse over the related topic.
Click the "Select Faculty Commentary" button to review full commentary.
Click on the tabs below to navigate between the two investigator treatment graphics and related commentary featured in this issue.

Front-line and maintenance therapy
for transplant-ineligible patients
Bone-targeted therapy and
Waldenström macroglobulinemia

WM = Waldenström macroglobulinemia; PN = peripheral neuropathy; NA = not applicable (faculty does not treat Waldenström macroglobulinemia); MM = multiple myeloma; BR = bendamustine/rituximab; DRC = dexamethasone/rituximab/cyclophosphamide; BTZ = bortezomib; FR = fludarabine/rituximab; VRD = bortezomib/rituximab/dexamethasone